TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02650258

Intervention type: BEHAVIORAL
Intervention: treadmill walking
Description: all participants walking at increasing speeds on a treadmill

Intervention type: BEHAVIORAL
Intervention: treadmill walking
Description: all participants walking at increasing speeds on a treadmill
Study: NCT04265742

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: bone densitometry
Description: Bone Mineral Density (BMD), body composition, vertebral fractures

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High resolution peripheral QCT
Description: High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength
Study: NCT02650258

Intervention type: BEHAVIORAL
Intervention: treadmill walking
Description: all participants walking at increasing speeds on a treadmill
Study: NCT02860975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaled Nitrogen
Description: To create the correct gas mixture, nitrogen tanks or membrane technology nitrogen generators will be utilized.~Humidified, high flow, hypoxic gas by nasal cannula will allow the participant to walk short distances, eat, execute basic personal needs (e.g., use of toilette, washing, bathing etc.), or take breaks from wearing the mask.
Study: NCT00107965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Description: 0.0025% PEP005 Topical Gel (Day 1,2 application)
Study: NCT04265742

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High resolution peripheral QCT
Description: High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High resolution peripheral QCT
Description: High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength
Study: NCT00107965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Description: 0.01% PEP005 Topical Gel (Day 1,2 application)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Description: 0.05% PEP005 Topical Gel (Day 1,2 application)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEP005
Description: Vehicle Gel (Day 1,2 application)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Description: 0.0025% PEP005 Topical Gel (Day 1,8 application)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Description: 0.01% PEP005 Topical Gel (Day 1,8 application)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005
Description: 0.05% PEP005 Topical Gel (Day 1,8 application)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEP005
Description: Vehicle Gel (Day 1,8 application)
Study: NCT02501954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo Radiation Therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo Radiation Therapy
Study: NCT04265742

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High resolution peripheral QCT
Description: High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Collection of biological samples
Description: Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Collection of biological samples
Description: Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Collection of biological samples
Description: Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Collection of biological samples
Description: Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition
Study: NCT01237041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin First
Description: Niacin 500 mg po four times on one of the inpatient days, then placebo on another inpatient day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin First
Description: Niacin 500 mg po four times on one of the inpatient days, then placebo on another inpatient day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo First
Description: Placebo po four times on one of the inpatient days, then Niacin 500 mg po four times on another inpatient day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo First
Description: Placebo po four times on one of the inpatient days, then Niacin 500 mg po four times on another inpatient day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-Establishing Study 1 Niacin 250mg
Description: Niacin 250 mg po three times at 2 hour intervals on an inpatient day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-Establishing Study 1 Niacin 500mg
Description: Niacin 500 mg po three times at 2 hour intervals on an inpatient day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-Establishing Study 2 Niacin 500mg
Description: Open-Label Niacin 500mg four times at 1 hour intervals on an inpatient day
Study: NCT04265742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Epidemiologic and nutritional questionnaire and physical activity scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Epidemiologic and nutritional questionnaire and physical activity scale
Study: NCT02772172

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Template

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Template
Study: NCT04726072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kundalini Yoga
Description: Participants met once a week for two hours for 12 weeks total. The Kundalini yoga intervention is a mixture of basic yoga, breathing exercises, and meditation. Participants were also asked to do at-home practice for half an hour daily.
Study: NCT04265742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Epidemiologic and nutritional questionnaire and physical activity scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Epidemiologic and nutritional questionnaire and physical activity scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical tests
Description: physical performance tests and grip strenght measurement
Study: NCT04726072

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants met once a week for two hours for 10 weeks total. The psychoeducation group acted as our control group and consisted of teaching participants about healthy aging. Participants were asked to do at-home practice for half an hour daily.
Study: NCT05672680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Bupivacaine
Description: received during TAP block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo equivalent
Study: NCT04265742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical tests
Description: physical performance tests and grip strenght measurement
Study: NCT02390726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study: NCT03116984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter arterial chemoembolization
Description: Transcatheter arterial chemoembolization (TACE) is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol was determined by diameter and blood supply type of HCC, generally 5-20ml, and no more than 30ml once.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External- beam radiotherapy
Description: We have reported a series of retrospective clinical trials in which transarterial chemoembolization (TACE) combined with external- beam radiotherapy (EBRT) was a better treatment method than TACE alone for unresectable HCC in the same period and organization, no matter in aspects of the regression rate of carcinoma or survival.Patients who were randomized to the EBRT 3-5 weeks after the completion 2 times TACE.
Study: NCT01487980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord clamping
Description: Early vs Delayed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cord clamping
Description: Early vs Delayed
Study: NCT00679328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical implantation of OP-1 device or autograft bone graft material
Description: Surgical implantation of OP-1 device or autograft bone graft material

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical implantation of OP-1 device or autograft bone graft material
Description: Surgical implantation of OP-1 device or autograft bone graft material
Study: NCT01133158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Bendamustine, Mitoxantrone, Dexamethasone
Description: Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
Study: NCT03721575

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scarpa's preserving hernio-abdominoplasty
Description: Scarpa's fascia is preserved during hernio-abdominoplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classical hernio-abdominoplasty
Description: Scarpa's fascia is removed during hernio-abdominoplasty
Study: NCT05462535

Intervention type: DRUG
Intervention: Amosartan Plus Tab.
Description: Amosartan Plus Tab., Once daily administered per the locally approved product information
Study: NCT02470130

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation
Description: 5 min of conversational relaxation red by one of the instructor between simulation and debriefing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation
Description: 5 min of conversational relaxation red by one of the instructor between simulation and debriefing
Study: NCT00658567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin tartrate (ACP-103)
Description: 10 mg, tablet, once daily by mouth, for six weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin tartrate (ACP-103)
Description: 20 mg, tablet, once daily by mouth, for six weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pimavanserin tartrate (ACP-103)
Description: Placebo, tablet, once daily by mouth, for six weeks
Study: NCT00831064

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy bowel prep
Description: PEG, bisacodyl, NaP, PSMC and Mg-citrate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy bowel prep
Description: PEG, bisacodyl, NaP, PSMC and Mg-citrate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy bowel prep
Description: PEG, bisacodyl, NaP, PSMC and Mg-citrate
Study: NCT04265742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical tests
Description: physical performance tests and grip strenght measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical tests
Description: physical performance tests and grip strenght measurement
Study: NCT03915951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: self-administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: self-administered orally
Study: NCT00831064

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy bowel prep
Description: PEG, bisacodyl, NaP, PSMC and Mg-citrate
Study: NCT03761303

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active rTMS
Description: The rTMS coil is applied tangentially to the head surface above the left DLPF (corresponding to position F3 of the international 10-20 system). For the stimulation intensity, the motor rest threshold of the patient is determined. The motor rest threshold is defined as the minimum intensity that triggers an EMG response with an amplitude\> 50 μV in the first right interosseus dorsalis muscle in at least 5 out of 10 cases. The stimulation intensity within the rTMS therapy is 80 percent of the motor rest threshold. In one session, 1,000 pulses are applied in 10 trains at a frequency of 10 Hz (1 train = 100 pulses in 10 s). Between the individual trains there is an inter-train interval of 28 seconds. The total duration of a session is 5:52 minutes. In total, the patient recieve 20 sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
Study: NCT03264651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enobosarm
Description: Oral combination therapy of enobosarm and anastrozole
Study: NCT04031482

Intervention type: OTHER
Intervention: No intervention, only standard care
Description: The aim of this registry is to expand on previous findings in the field of diagnostic and therapeutic pathways for patients with Crohn's disease, ulcerative colitis and indeterminate colitis undergoing routine administration of a targeted therapy (biologics or another targeted therapy such as Janus kinase therapy) and various different treatment approaches. A data pool is to be generated for this purpose, in order to~* analyse disease progression~* systematize findings about treatment processes~* identify potential influencing factors~* review any new diagnostic procedures~* identify potential test subjects for further study~* evaluate the safety of various treatment concepts
Study: NCT01265602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41007
Description: Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LASW1510
Description: Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of LAS41007
Description: Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
Study: NCT00435279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Eszopiclone 3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
Study: NCT04093674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: de-epithelized (DE) SCTG
Description: subepithelial connective tissue grafts

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: de-epithelized (DE) SCTG
Description: subepithelial connective tissue grafts

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: de-epithelized (DE) SCTG
Description: subepithelial connective tissue grafts
Study: NCT03042858

Intervention type: OTHER
Intervention: Infants with PPV
Description: Data will be collected for up to 18 years to monitor for inguinal hernia.

Intervention type: OTHER
Intervention: Infants without PPV
Description: Basic data will be collected regarding the surgery and the subject's study participation will be complete.
Study: NCT00303017

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavocoxid
Description: flavonoid mixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: non-steroidal anti-inflammatory drug
Study: NCT00734851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBXRT
Description: External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.
Study: NCT02259569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume-controlled ventilation
Study: NCT03941769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interleukin-7
Description: Given IM or SC
Study: NCT05672680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: The intervention is a transabdominal plane (TAP) block given in the abdomen to block pain receptors on nerves -during surgery can presumably decrease postoperative pain. Currently, TAP blocks are approved for use and performed based on surgeon preference (e.g. some surgeons perform them on every case, others variably, etc.).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block
Description: The intervention is a transabdominal plane (TAP) block given in the abdomen to block pain receptors on nerves -during surgery can presumably decrease postoperative pain. Currently, TAP blocks are approved for use and performed based on surgeon preference (e.g. some surgeons perform them on every case, others variably, etc.).
Study: NCT03386643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis HN019
Description: The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 for mouthwash twice a day for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate 0.05%
Description: The selected patients will receive capsules to be diluted in 15ml of water containing clobetasol propionate 0.05% for mouthwash twice a day for 4 weeks.
Study: NCT01808079

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02322658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone Tablets 3 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone Tablets 3 mg
Study: NCT01528826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine plus oxaliplatin
Description: Vinorelbine 30mg/m2 IVGTT D1 Oxaliplatin 90mg/m2 IVGTT D1; every 2 weeks
Study: NCT03604887

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: Ultrasound evaluation will be done with transducer abdominal probe. The amount of amniotic fluid and umbilical cord sections will be determined by evaluating the images obtained from the sagittal plane in the ultrasound evaluations in the 4 abdominal quadrants.~When the anatomical structure of the umbilical cord is considered, it is folded in amniotic fluid. The folds appear as umbilical cord rings, side-by-side at the sagittal sections.~Scoring of umbilical cord length index~* 1 point will be given for each quadrant where the umbilical cord was observed.~* 0.5 point will be given for each umbilical cord ring in one quadrant. Every quadrant will be evaluated in this manner, and the total score will be calculated.
Study: NCT03294356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT210771
Description: An electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT210751
Description: An electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6T30134157764
Description: An electronic cigarette
Study: NCT03503370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
Study: NCT03294356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G41A7C071
Description: An electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M011161212
Description: An electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21002
Description: A combustible cigarette
Study: NCT00894907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PiCCO-parameter-guided volume resuscitation
Description: Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids with the following goals:~ITBI: 850-1000 ml/sqm, if ELWI \<=12\*ml/kg; ITBI 750-850 ml/sqm, if ELWI \>12\*ml/kg and/or PaO2:FiO2 \<200 (\*ELWI\<=12ml/kg, if MAP\>65mmHg without catecholamines; ELWI\<=14ml/kg, if catecholamines required for MAP\>65mmHg); SVV\<10% (only in controlled ventilation and sinus rhythm); MAP\>65mmHg (MAP: Mean Arterial Pressure); IAPP \>60mmHg (IAPP: Intra-abdominal Perfusion Pressure)

Intervention type: OTHER
Group type: OTHER
Intervention: Control-group
Description: Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.~Main haemodynamic goals: CVP 8-12 mmHg; MAP \>65mmHg;IAPP \>60mmHg
Study: NCT02139514

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Social Cognition Training
Description: Social skills training via virtual reality with trained therapist.